VIDEO and FREE TRIAL
Qlucore Omics Explorer video
Qlucore Omics Explorer free trial
Board of Directors
Pia Gideon
Chairman
Pia Gideon has a degree in business administration from the Stockholm School of Economics and has broad experience in senior positions in global operations, marketing and communication, and leadership coaching. Pia also has broad experience in chairman and board assignments in listed, state-owned and start-up companies, specializing in technology and health healthcare.
Currently on the board of Apoteket, Devyser Diagnostics AB, and Skandi Standard AB.
Board member since 2009 and chairman of the board since 2018. Holds 25 410 shares through a company controlled by her.
Independent in relation to the company and its management, independent in relation to its major shareholders.
Thoas Fioretos
Thoas Fioretos is a professor and chief physician in clinical genetics at Lund University. He specializes in genomics-based precision medicine focusing on acute leukemia and has published more than 125 scientific articles. Thoas Fioretos has extensive experience in developing new methods for improved clinical diagnostics within cancer based on genetic analyses. Thoas Fioretos are further founders of Qlucore and Cantargia. He is a member of the Royal Swedish Academy of Sciences. Thoas is also one of the initiators of Genomic Medicine Sweden.
Currently on the board of Lead Biologics Intl, Neodos AB, and Coegin Pharma.
Board member since 2007. Holds 184 430 shares.
Dependent in relation to the company and its management, independent in relation to its major shareholders.
Magnus Fontes
Magnus Fontes has a Ph.D. in Mathematics and has previously been a Professor of Mathematics at Lund University and a Professor of Bioinformatics at Copenhagen University.
Furthermore, Magnus Fontes has previously been Head of International Relations at the Center for Bioinformatics, Biostatistics, and Integrative Biology at Pasteur Institute in Paris. Magnus Fontes has since 2017 been a leader in Genentech's research efforts in Systems Cancer Immunology. Magnus Fontes has broad academic experience in applied Mathematics and has been head of the Institute Roche in France since 2020. He is particularly an expert in mathematical modeling, statistical learning, and bioinformation.
Board member since 2007. Holds 186 460 shares.
Independent in relation to the company and its management, independent in relation to its major shareholders.
Carl-Johan Ivarsson
CEO
Carl-Johan Ivarsson has a master's degree in electrical engineering from Lund University and has more than 25 years of experience in software development, product management, and sales He has been CEO of Qlucore since 2007. Carl-Johan previously worked for a long time as Vice President with responsibility for product management at Ericsson Mobile Platforms.
Board member since 2007. Holds 346 460 shares and 12 144 warrants.
Dependent in relation to the company and its management, dependent in relation to the company’s major shareholders.
Boel Sundvall
Boel Sundvall has a master's degree in economics from the Stockholm School of Economics. Boel has extensive experience in finance, corporate finance, investor relations, and communication and has been a member of group management in several listed global groups.
Currently on the board of EBS Invest AB.
Board member since 2019. Holds 6,500 shares directly and indirectly through a company controlled by her.
Independent in relation to the company and its management, independent in relation to its major shareholders.
Helle Fisker
Helle Fisker has a master's degree in Biotechnology and an Executive MBA. Helle has more than 20 years of experience in senior sales and marketing roles in the fields of Medtech and Biotech. She has extensive commercial experience from taking to the global market more than 300 tests for cancer diagnostics, applications for digital Pathology, as well as Oncology treatments and vaccines in Denmark. She is currently working as VP of Commercialization for Biovica.
Currently on the board of Flow Robotics A/S.
Holds 5 000 shares. Independent in relation to the company and its management, independent in relation to its major shareholders.
Lars Höckenström
Lars Höckenström has an MBA with long and broad experience in the financial sector. Lars Höckenström has ongoing assignments within Devyser Diagnostics AB, Gårdarike AB, Gårdarike Fastigheter AB, Gårdarike Invest Aktiebolag, AB Consiliario, Guard Therapeutics International AB (publ), and Cloudbackend AB.
Previous assignments have been as co-founder and partner of Aragon FK AB, analyst at Öhman FK AB and Pareto Securities AB, analyst and portfolio manager at Catella Kapitalförvaltning AB, co-founder and senior advisor at Naventus Corporate Finance AB, board member of Klövern AB, board member of RhoVac AB, deputy member of Gårdarike Fastigheter AB, Gårdarike Invest Aktiebolag, Gårdarike AB and SHLM OXN Holding AB.
Independent in relation to the company and its management, independent in relation to its major shareholders. Board member since 2023.